We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Inc. (BIIB - Free Report) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Shares of Biogen rose more almost 5% in pre-market trading in response to the strong results. However, we note that Biogen’s shares declined 2.3% so far this year, which compares unfavorably with the Zacks classified Medical-Biomed/Genetics industry’s increase of 3.2%.
Coming back to the results, Biogen reported first-quarter 2017 earnings per share of $5.20, which beat the Zacks Consensus Estimate of $4.97 by 4.6%. The bottom line also improved 9% year over year.
Sales came in at $2.81 billion, up 3% from the year-ago period. Sales also surpassed the Zacks Consensus Estimate of $2.73 billion by 2.9%. The top line, excluding hemophilia revenues, grew 8%. The company spun off its hemophilia business in Feb 2017.
Quarter in Detail
Sales of oral multiple sclerosis (MS) drug Tecfidera rose 1% from the year-ago period to $958 million. However, the drug recorded a 4.4% sequential decline in revenues. This included U.S. sales of $751.1 million and ex-U.S. sales of $207.1 million.
First-quarter Tysabri revenues increased 14% year over year and 15% sequentially to $545 million (U.S. $305.5 million, ex-U.S. $239.5 million).
Combined interferon revenues (Avonex and Plegridy) in the first quarter were $648.3 million (U.S. $464.8 million, ex-U.S. $183.5 million), down 3.3% from the year-ago period and 5.8% sequentially. Avonex revenues declined 5% from the year-ago period to $537 million.
Plegridy contributed $112 million to first-quarter 2017 revenues, up 5% year over year but down 10% sequentially.
Zinbryta, which was launched in collaboration with AbbVie Inc. (ABBV - Free Report) in August last year, contributed $10.7 million to revenues in the quarter compared with $5.9 million in fourth-quarter 2016.
In the quarter, Biogen recorded biosimilar revenues of $66 million compared with $53 million in fourth-quarter 2016. Biogen markets Flixabi, a biosimilar referencing Johnson & Johnson’s (JNJ - Free Report) blockbuster drug Remicade. The company also markets Benepali, a biosimilar referencing Amgen Inc.’s (AMGN - Free Report) Enbrel in Europe.
Revenues from Anti-CD20 therapeutic programs, which include Biogen’s share of Rituxan and Gazyva operating profits, increased 3.4% from the year-ago period to $340.6 million in the first quarter.
Newly launched Spinraza brought revenues of $47.4 million in the first quarter compared with $4.6 million in fourth-quarter 2016. The company said that Spinraza, approved for the treatment of patients with spinal muscular atrophy, is off to a strong start. Sales in the quarter were much better than market expectations.
In April, Biogen announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing approval for Spinraza in the EU.
Research and development expenses rose 4% in the reported quarter to $421 million, SG&A spend increased 3% year over year to $483 million.
In the quarter, the company repurchased shares worth $584 million.
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
Biogen Inc. (BIIB - Free Report) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
Shares of Biogen rose more almost 5% in pre-market trading in response to the strong results. However, we note that Biogen’s shares declined 2.3% so far this year, which compares unfavorably with the Zacks classified Medical-Biomed/Genetics industry’s increase of 3.2%.
Coming back to the results, Biogen reported first-quarter 2017 earnings per share of $5.20, which beat the Zacks Consensus Estimate of $4.97 by 4.6%. The bottom line also improved 9% year over year.
Sales came in at $2.81 billion, up 3% from the year-ago period. Sales also surpassed the Zacks Consensus Estimate of $2.73 billion by 2.9%. The top line, excluding hemophilia revenues, grew 8%. The company spun off its hemophilia business in Feb 2017.
Quarter in Detail
Sales of oral multiple sclerosis (MS) drug Tecfidera rose 1% from the year-ago period to $958 million. However, the drug recorded a 4.4% sequential decline in revenues. This included U.S. sales of $751.1 million and ex-U.S. sales of $207.1 million.
First-quarter Tysabri revenues increased 14% year over year and 15% sequentially to $545 million (U.S. $305.5 million, ex-U.S. $239.5 million).
Combined interferon revenues (Avonex and Plegridy) in the first quarter were $648.3 million (U.S. $464.8 million, ex-U.S. $183.5 million), down 3.3% from the year-ago period and 5.8% sequentially. Avonex revenues declined 5% from the year-ago period to $537 million.
Plegridy contributed $112 million to first-quarter 2017 revenues, up 5% year over year but down 10% sequentially.
Zinbryta, which was launched in collaboration with AbbVie Inc. (ABBV - Free Report) in August last year, contributed $10.7 million to revenues in the quarter compared with $5.9 million in fourth-quarter 2016.
In the quarter, Biogen recorded biosimilar revenues of $66 million compared with $53 million in fourth-quarter 2016. Biogen markets Flixabi, a biosimilar referencing Johnson & Johnson’s (JNJ - Free Report) blockbuster drug Remicade. The company also markets Benepali, a biosimilar referencing Amgen Inc.’s (AMGN - Free Report) Enbrel in Europe.
Revenues from Anti-CD20 therapeutic programs, which include Biogen’s share of Rituxan and Gazyva operating profits, increased 3.4% from the year-ago period to $340.6 million in the first quarter.
Newly launched Spinraza brought revenues of $47.4 million in the first quarter compared with $4.6 million in fourth-quarter 2016. The company said that Spinraza, approved for the treatment of patients with spinal muscular atrophy, is off to a strong start. Sales in the quarter were much better than market expectations.
In April, Biogen announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing approval for Spinraza in the EU.
Research and development expenses rose 4% in the reported quarter to $421 million, SG&A spend increased 3% year over year to $483 million.
In the quarter, the company repurchased shares worth $584 million.
Biogen Inc. Price, Consensus and EPS Surprise
Biogen Inc. Price, Consensus and EPS Surprise | Biogen Inc. Quote
Zacks Rank & Key Picks
Biogen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>